Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-17T15:19:52.434Z Has data issue: false hasContentIssue false
  • English
  • Français

The intraoperative use of recombinant activated factor VII in arterial switch operations

Published online by Cambridge University Press:  19 November 2020

Jessica Zink ,
Zachary A. Spigel Open the ORCID record for Zachary A. Spigel [Opens in a new window] ,
Christopher Ibarra Open the ORCID record for Christopher Ibarra [Opens in a new window] ,
Erin A. Gottlieb ,
Iki Adachi ,
Carlos M. Mery ,
Michiaki Imamura ,
Jeffrey S. Heinle ,
Emmett Dean McKenzie  and
Charles D. Fraser
...Show all authors
Jessica Zink
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Zachary A. Spigel
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Christopher Ibarra
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Erin A. Gottlieb
Affiliation:
Dell Children’s Medical Center of Central Texas, Austin, TX, USA
Iki Adachi
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Carlos M. Mery
Affiliation:
Dell Children’s Medical Center of Central Texas, Austin, TX, USA
Michiaki Imamura
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Jeffrey S. Heinle
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Emmett Dean McKenzie
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
Charles D. Fraser
Affiliation:
Dell Children’s Medical Center of Central Texas, Austin, TX, USA
Ziyad M. Binsalamah*
Affiliation:
Texas Children’s Hospital, Houston, TX, USA
*
Author for correspondence: Ziyad M. Binsalamah, MD, MSc, FRCSC, Division of Congenital Heart Surgery, Texas Children’s Hospital; Michael E. DeBakey Department of Surgery, Baylor College of Medicine 6651 Main street, LT19345H, Houston, TX 77030, USA. Tel: +1 832 826 1929; Fax: +1 832 825 1905. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The rate of bleeding complications following arterial switch operation is too low to independently justify a prospective randomised study for benefit from recombinant factor VIIa. We aimed to evaluate factor VIIa in a pilot study.

Methods:

We performed a retrospective cohort study of patients undergoing arterial switch operation from 2012 to 2017. Nearest-neighbour propensity score matching on age, gender, weight, and associated cardiac defects was used to match 27 controls not receiving recombinant factor VIIa to 30 patients receiving recombinant factor VIIa. Fisher’s exact test was performed to compare categorical variables. Wilcoxon’s rank-sum test was used to compare continuous variables between cohorts.

Results:

Post-operative thrombotic complications were not associated with factor VIIa administration (Odds Ratio (OR) 0.28, 95% CI 0.005–3.77, p = 0.336), nor was factor VIIa administration associated with any re-explorations for bleeding. No intraoperative transfusion volumes were different between the recombinant factor VIIa cohort and controls. Post-operative prothrombin time (10.8 [10.3–12.3] versus 15.9 [15.1–17.2], p < 0.001) and international normalised ratio (0.8 [0.73–0.90] versus 1.3 [1.2–1.4], p < 0.001]) were lower in recombinant factor VIIa cohort relative to controls.

Conclusions:

In spite of a higher post-bypass packed red blood cell transfusion requirement, patients receiving recombinant factor VIIa had a similar incidence of bleeding post-operatively. With no difference in thrombotic complications, and with improved post-operative laboratory haemostasis, a prospective randomised study is warranted to evaluate recombinant factor VIIa.

Keywords

Arterial switch operationrecombinant factor VIIahaemostasis
Type
Original Article
Information
Cardiology in the Young , Volume 31 , Issue 3 , March 2021 , pp. 386 - 390
Check for updates
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Southern Thoracic Surgical Association 66th Annual Meeting, Marco Island, FL, USA.

References

Wickham, H. ggplot2: ggplot2. Wiley Interdiscip Rev Computat Stat 2011; 3: 180–185. doi: 10.1002/wics.147 CrossRefGoogle Scholar
Bercovitz, RS, Shewmake, AC, Newman, DK, et al. Validation of a definition of excessive postoperative bleeding in infants undergoing cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 2018; 155: 2112–2124.CrossRefGoogle ScholarPubMed
Faraoni, D. Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: one size doesn’t fit all. J Thorac Cardiovasc Surg 2018; 155: 2125–2126.CrossRefGoogle ScholarPubMed
O’Connell, KA, Wood, JJ, Wise, RP, Lozier, JN, Braun, MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293–298.CrossRefGoogle ScholarPubMed
Fraser, CD. The neonatal arterial switch operation: how I teach it. Ann Thorac Surg 2016; 102: 681–684.CrossRefGoogle Scholar
Ekert, H, Brizard, C, Eyers, R, Cochrane, A, Henning, R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006; 17: 389–395.CrossRefGoogle ScholarPubMed
Niles, SD, Burkhart, HM, Duffey, DA, Buhrman, K, Burzynski, J, Holt, DW. Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery. J Extra Corpor Technol 2008; 40: 241.Google Scholar
Christoff, AS, Winlaw, DS, Curtin, J, Barnes, EH, Egan, JR. Recombinant activated factor VII in neonatal cardiac surgery. Eur J Cardiothorac Surg 2019; 55: 817–822.CrossRefGoogle ScholarPubMed
Li, Y, Zhao, W, Luo, Q, Wu, X, Ding, J, Yan, F. A propensity-score matched analysis on outcomes using recombinant activated factor VII in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 2019; 33: 1269–1275.CrossRefGoogle ScholarPubMed
Changlani, DK, Devendaran, V, Murmu, UC, Ganesan, S, Varghese, R, Kumar, RS. Factor VII for excessive bleeding following congenital heart disease surgery. Asian Cardiovasc Thorac Ann 2012; 20: 120–125.CrossRefGoogle ScholarPubMed